Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study

10.1016/s0140-6736(08)60593-0 ◽

2008 ◽

Vol 371 (9621) ◽

pp. 1337-1342 ◽

Author(s):

K Papp ◽

R Bissonnette ◽

L Rosoph ◽

N Wasel ◽

CW Lynde ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

Journal of the American Academy of Dermatology ◽

10.1067/mjd.2002.127247 ◽

2002 ◽

Vol 47 (6) ◽

pp. 821-833 ◽

Author(s):

Gerald G. Krueger ◽

Kim A. Papp ◽

Dow B. Stough ◽

Keith H. Loven ◽

Wayne P. Gulliver ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/s0093-3619(08)79136-6 ◽

2009 ◽

Vol 2009 ◽

pp. 131-132

Author(s):

B.H. Thiers

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Case Medical Research ◽

10.31525/ct1-nct04033354 ◽

2019 ◽

Author(s):

Keyword(s):

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text

Faculty Opinions recommendation of Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717962498.793465528 ◽

2012 ◽

Author(s):

David Alpers

Keyword(s):

Peritoneal Carcinomatosis ◽

Bowel Obstruction ◽

Symptomatic Treatment ◽

Phase Iii ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718340215.793493941 ◽

2014 ◽

Author(s):

Kamran Ghoreschi ◽

Sebastian Volc

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Phase Iii Study

Download Full-text

PIII-38Long-term effects of ramelteon on endocrine function in patients with chronic insomnia in a double-blind, placebo-controlled phase III study

Clinical Pharmacology & Therapeutics ◽

10.1016/j.clpt.2005.12.246 ◽

2006 ◽

Vol 79 (2) ◽

pp. P68-P68 ◽

Author(s):

G RICHARDSON ◽

S WANGWEIGAND ◽

S SAINATI ◽

S DEMISSIE

Keyword(s):

Endocrine Function ◽

Phase Iii ◽

Chronic Insomnia ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study

Download Full-text

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2014.01.897 ◽

2014 ◽

Vol 71 (3) ◽

pp. 484-492 ◽

Author(s):

D.S. Krupashankar ◽

Sunil Dogra ◽

Mahendra Kura ◽

Abir Saraswat ◽

Leelavathy Budamakuntla ◽

...

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Efficacy, safety, and gastrointestinal tolerability of tapentadol ER in a randomized, double-blind, placebo- and active-controlled phase III study of patients with chronic low back pain

Journal of Pain ◽

10.1016/j.jpain.2009.01.202 ◽

2009 ◽

Vol 10 (4) ◽

pp. S48 ◽

Author(s):

R. Buynak ◽

D. Shapiro ◽

A. Okamoto ◽

C. Lange ◽

M. Etropolski

Keyword(s):

Low Back Pain ◽

Back Pain ◽

Chronic Low Back Pain ◽

Phase Iii ◽

Low Back ◽

Double Blind ◽

Double Blind Placebo ◽

Gastrointestinal Tolerability ◽

Phase Iii Study

Download Full-text

Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study

Advances in Therapy ◽

10.1007/s12325-021-01899-0 ◽

2021 ◽

Author(s):

Lin Cai ◽

Linfeng Li ◽

Hao Cheng ◽

Yangfeng Ding ◽

Zhenshu Biao ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Phase Iii Study

Download Full-text